Citations

Mayo Clinic

Showing 10 of 108585 citations.

The Therapeutic Efficacy of Freeze-Dried Human Amniotic Membrane Allograft Gel for Diabetic Foot Ulcers: A Phase-1 Clinical Trial
Rezaeinejad, Aida , Amirkhani, Mohammad-Amir, Ghorani, Seyyed Mojtaba , Alamoutifard, Emad, Nilforoushzadeh, Mohammadali , Sisakht, Mahsa Mollapour , Rezaei-Nejad, Aida , Mollapour-Sisakht, Mahsa , Amirkhani, Mohammad Amir , Ebrahimi, Alireza

The International Journal of Lower Extremity Wounds | October 13, 2023 | Volume: 25 | Issue: 1 | Pages: 163-173

10.1177/15347346231204246 | PMID 37828852 Get It

Diabetic foot ulcers (DFUs) are classified as hard-to-heal wounds, which occur in approximately 15% of diabetic patients. Several interventions have shown efficacy in reducing the risk of amputation among patients with DFU, including timely diagnosis and management of infection and ischemia, debridement of necrotic tissues, reducing mechanical pressure on ulcers, and patient education. One major challenge in the management of DFUs is optimizing wound care to improve healing outcomes. Recently, interdisciplinary approaches proposed a new generation of wound dressing which increased efficacy and significantly decreased the healing time. The current study assessed the healing characteristics of chronic DFUs treated with lyophilized amniotic membrane gel (LAMG) in combination with standard care, versus a placebo hydrogel with standard care. In total, 18 patients (8 male, 10 female) were randomly assigned to the control group, which received standard care and a gelatin scaffold (placebo), or the intervention group, which received standard care along with LAMG. We evaluated the reduction in wound size and assessed the patient's health-related quality of life over 9 weeks. In the LAMG group (n = 9) and the Placebo group (n = 9), the wounds were reduced in size by a mean of 73.4% ± 15.3% and 13.1% ± 10.1%, respectively ( P = .008). Patients treated with LAMG demonstrated significant improvements in the scores related to physical function, physical limitation, physical pain, general health, social function, emotional problems, and energy levels compared to the control group. The findings of this study indicate that using the LAMG with standard care significantly enhances wound healing.
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma
Vaubel, Rachael A. , Oh, Ju-Hee, Mladek, Ann C. , Talele, Surabhi , Zhang, Wenqiu , Waller, Katie L. , Burgenske, Danielle M. , Sarkaria, Jann N. , Elmquist, William F. , Zhang, Wenjuan , Vaubel, Rachael A , Oh, Ju-Hee , Mladek, Ann C , Talele, Surabhi , Zhang, Wenqiu , Waller, Katie L , Burgenske, Danielle M , Sarkaria, Jann N , Elmquist, William F , Zhang, Wenjuan

Molecular Cancer Therapeutics | October 13, 2023 | Volume: 23 | Issue: 1 | Pages: 47-55

10.1158/1535-7163.mct-23-0217 | PMID 37828724 Get It

Abstract MDM2–p53 inhibition may be effective in glioblastoma (GBM). This study evaluates the pharmacokinetics/pharmacodynamics of BI-907828, a potent antagonist of MDM2, in GBM, and demonstrates a translational paradigm with a focus on a unified “Delivery – Potency – Efficacy” relationship in drug development for central nervous system(CNS) tumors. BI-907828 was tested for cytotoxicity and MDM2–p53 pathway inhibition. Systemic pharmacokinetics and transport mechanisms controlling CNS distribution were evaluated in mice. BI-907828 free fractions in cell media, mouse and human specimens were measured to determine “active” unbound concentrations. Efficacy measures, including overall survival and target expression were assessed in mouse orthotopic GBM xenografts. BI-907828 exhibited potent inhibition of MDM2–p53 pathway and promoted cell death in GBM TP53 wild-type cells. MDM2-amplified cells are highly sensitive to BI-907828, with an effective unbound concentration of 0.1 nmol/L. The CNS distribution of BI-907828 is limited by blood–brain barrier (BBB) efflux mediated by P-gp, resulting in a Kp,uu_brain of 0.002. Despite this seemingly “poor” BBB penetration, weekly administration of 10 mg/kg BI-907828 extended median survival of orthotopic GBM108 xenografts from 28 to 218 days (P < 0.0001). This excellent efficacy can be attributed to high potency, resulting in a limited, yet effective, exposure in the CNS. These studies show that efficacy of BI-907828 in orthotopic models is related to high potency even though its CNS distribution is limited by BBB efflux. Therefore, a comprehensive understanding of all aspects of the “Delivery – Potency – Efficacy” relationship is warranted in drug discovery and development, especially for treatment of CNS tumors.
Reactive Granulomatous Dermatitis in a Child with Acute Lymphoblastic Leukemia
Tolson, Hannah C. , McCune, Mariana, Yousif, Miranda , DiCaudo, David J. , Dupuy, Elizabeth , DiCaudo, David

Case Reports in Dermatological Medicine | October 12, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-5

10.1155/2023/3428162 | PMID 37869105 Get It

Reactive granulomatous dermatitis (RGD) is an umbrella term to describe a reaction pattern characterized by skin-colored to erythematous papules, plaques, and nodules although other morphologies have been described. RGD has rarely been reported in children, and in this report, we present the case of a 3-year-old girl with acute lymphoblastic leukemia (ALL) who presented with firm, tender nodules, and ulcerated plaques on her extremities. Histopathologic examination showed foci of dense granulomatous inflammatory infiltrates composed of histiocytes, neutrophils, and multinucleate giant cells. The constellation of clinical symptoms, negative infectious workup, and histopathology support the diagnosis of RGD.
Evaluation of Robustness of S-Transform Based Phase Velocity Estimation in Viscoelastic Phantoms and Renal Transplants
Kijanka, Piotr , Vasconcelos, Luiz , Mandrekar, Jay , Urban, Matthew W. , Mandrekar, Jayawant N. , Vasconcelos, Luiz , Urban, Matthew W

IEEE Transactions on Biomedical Engineering | October 12, 2023 | Volume: 71 | Issue: 3 | Pages: 954-966

10.1109/tbme.2023.3323983 | PMID 37824308 Get It

A Dojo Without Diversity
Ishimoto, Alyssa K. , Abdulwadood, Isra

Academic Medicine | October 12, 2023 | Volume: 99 | Issue: 6 | Pages: e16-e16

10.1097/acm.0000000000005496 | PMID 37824843 Get It

Covered in the Operating Room: Carving Out Space for My Hijab
Abdulwadood, Isra , Ishimoto, Alyssa K.

Academic Medicine | October 12, 2023 | Volume: 99 | Issue: 6 | Pages: e2-e2

10.1097/acm.0000000000005495 | PMID 37824842 Get It

Challenges and solutions of echocardiography generalization for deep learning: a study in patients with constrictive pericarditis
Jeong, Jiwoong , Pelkey, Melissa N. , Chen, Yi‐Chieh , Ramzan, Raheel N., Elbahnasawy, Mohammad , Sleem, Mohamed, Grogan, Martha , Kane, Garvan C. , Patel, Bhavik N. , Oh, Jae K. , Banerjee, Imon , Chao, Chieh-Ju , Arsanjani, Reza , Kim, Kihong, Pelkey, Melissa N , Chen, Yi-Chieh , Farina, Juan Maria M, Banerjee, Imon , Chao, Chieh‐Ju , Arsanjani, Reza , Kim, Kihong , Farina, Juan M.

Journal of Medical Imaging | October 12, 2023 | Volume: 10 | Issue: 05 | Pages: No page available

10.1117/1.jmi.10.5.054502 | PMID 37840850 Get It

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial
Papazoglou, Despoina , Wang, Victoria , Shanafelt, Tait D. , Lesnick, Connie , Rossi, Giulia De , Herter, Sylvia , Bacac, Marina , Klein, Christian , Tallman, Martin S. , Ramsay, Alan G. , Lesnick, Connie E, De Rossi, Giulia , Kay, Neil E , Ramsay, Alan G , Shanafelt, Tait D , Ioannou, Nikolaos , Kay, Neil E.

Blood | October 12, 2023 | Volume: 143 | Issue: 1 | Pages: 57-63

10.1182/blood.2023020554 | PMID 37824808 Get It

Abstract Bruton tyrosine kinase inhibitors (BTKis) that target B-cell receptor signaling have led to a paradigm shift in chronic lymphocytic leukemia (CLL) treatment. BTKis have been shown to reduce abnormally high CLL-associated T-cell counts and the expression of immune checkpoint receptors concomitantly with tumor reduction. However, the impact of BTKi therapy on T-cell function has not been fully characterized. Here, we performed longitudinal immunophenotypic and functional analysis of pretreatment and on-treatment (6 and 12 months) peripheral blood samples from patients in the phase 3 E1912 trial comparing ibrutinib-rituximab with fludarabine, cyclophosphamide, and rituximab (FCR). Intriguingly, we report that despite reduced overall T-cell counts; higher numbers of T cells, including effector CD8+ subsets at baseline and at the 6-month time point, associated with no infections; and favorable progression-free survival in the ibrutinib-rituximab arm. Assays demonstrated enhanced anti-CLL T-cell killing function during ibrutinib-rituximab treatment, including a switch from predominantly CD4+ T-cell:CLL immune synapses at baseline to increased CD8+ lytic synapses on-therapy. Conversely, in the FCR arm, higher T-cell numbers correlated with adverse clinical responses and showed no functional improvement. We further demonstrate the potential of exploiting rejuvenated T-cell cytotoxicity during ibrutinib-rituximab treatment, using the bispecific antibody glofitamab, supporting combination immunotherapy approaches.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Barocas, Daniel A. , Bitting, Rhonda L. , Bryce, Alan H. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Guzzo, Thomas, Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Shead, Dorothy A. , Snedeker, Jenna, Freedman-Cass, Deborah A., Bryce, Alan, Bryce, Alan H , Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Netto, George J. , Spratt, Daniel E. , Teply, Benjamin A. , Tward, Jonathan D.

Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1067-1096

10.6004/jnccn.2023.0050 | PMID 37856213 Get It

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
Churpek, Jane , Kohlmann, Wendy , Al‐Hilli, Zahraa , Friedman, Susan , Hagemann, Andrea R. , Hendrix, Ashley, Hutton, Mollie L., Kassem, Nawal , Khan, Seema, Khoury, Katia , Kurian, Allison W. , Laronga, Christine , Mak, Julie , Mansour, John C. , McDonnell, Kevin , Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Rash, Dominique , Reiser, Gwen , Senter-Jamieson, Leigha, Shannon, Kristen M. , Visvanathan, Kala , Welborn, Jeanna, Wick, Myra , Wood, Marie , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Norquist, Barbara M. , Churpek, Jane E. , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Churpek, Jane E , Daly, Mary Beryl , Pal, Tuya , Maxwell, Kara N. , Arun, Banu , Buys, Saundra S. , Cheng, Heather H. , Domchek, Susan M. , Giri, Veda N. , Goggins, Michael , Karlan, Beth Y.

Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1000-1010

10.6004/jnccn.2023.0051 | PMID 37856201 Get It

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1 , BRCA2 , CDH1 , PALB2 , PTEN , and TP53 , and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.